WSJ Zoetis article does not bring new information, says William Blair

William Blair says the Wall Street Journal article on safety concerns around Zoetis’ Librela and Solensia drugs for dog and cast osteoarthritis pain does not introduce new information into the ongoing safety debate. The article highlights a couple of anecdotal cases where pets experienced serious adverse events and includes additional context with veterinary quotes on the products, the analyst tells investors in a research note. The firm acknowledges headline risk from the story but says its talks with management support a bullish view on Librela. Blair maintains an Outperform rating on Zoetis.